Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.

Olaparib plus temozolomide was associated with a 27% overall response rate among 22 patients with pretreated uterine leiomyosarcoma.

The results of the phase 3 MASTERKEY-265 trial show that there is still an unmet need for patients who are refractory to pembrolizumab and anti–PD-1 inhibitors.

Oncology nurses at the 2022 ASTCT Meeting shared how a peer-to-peer observation and validation tool helped decrease central line-associated bloodstream infections by 68%.

The use of PARP inhibitor olaparib in conjunction with temozolomide may be an effective treatment for patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype.

Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women.